Roche Tissue Diagnostics

What Roche Tissue Diagnostics does

Roche Tissue Diagnostics is the tissue diagnostics division of Roche Diagnostics Corporation, a subsidiary of F. Hoffmann-La Roche Ltd headquartered in Basel, Switzerland, with primary US operations in Indianapolis. The division specializes in tissue-based diagnostics for oncology and other diseases, operating primarily under the VENTANA brand. Its core technology portfolio spans automated immunohistochemistry (IHC) and in situ hybridization (ISH) staining platforms led by the BenchMark ULTRA system, alongside the broader Roche Diagnostics family of molecular diagnostic systems (cobas 5800/6800/8800), digital PCR (Digital LightCycler), clinical chemistry (cobas c 703, ISE neo), and next-generation sequencing (AXELIOS 1). The Digital Pathology Dx whole slide imaging system, validated for primary diagnosis in surgical pathology, represents the company's AI-enabled diagnostic platform with computer vision capabilities for biomarker auto-detection.

The company generates revenue through three primary streams: instrument and system sales (hardware), recurring consumable reagents and assays (one-time license style contracts), and licensing/royalty revenue from companion diagnostic partnerships with pharmaceutical companies. Go-to-market is built on a global enterprise field sales model with dedicated technical specialists supporting hospital and reference laboratory customers, complemented by online ordering through the eLabDoc customer portal. Customer segments span pathology laboratories (primary), clinical and molecular laboratories, core hospital laboratories, and pharmaceutical companies developing targeted therapies. The company is identified as one of three key players in the global AI-based digital pathology market alongside PathAI and Paige, and continues to expand its diagnostics portfolio through FDA-cleared innovations including the Elecsys pTau181 blood test for Alzheimer's disease (October 2025), the AXELIOS 1 sequencing platform (2026), and the cobas c 703 and ISE neo analytical units (2026). Long-standing partnerships include a 20+ year exclusive arrangement with TIB Molbiol for LightMix assays and recent collaborations with CelLBxHealth and Eli Lilly.

Name

Roche Tissue Diagnostics

Legal name

Roche Diagnostics Corporation

Website

https://diagnostics.roche.com

Company type

Private

Founded year

1896

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Roche Tissue Diagnostics is a division of Roche Diagnostics specializing in tissue-based diagnostics for oncology, providing automated IHC/ISH staining systems, companion diagnostics, and AI-enabled digital pathology solutions to pathology laboratories, hospitals, and pharmaceutical partners worldwide.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI)

akta.pro secondary industries

Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

Keywords

• Tissue diagnostics
• Immunohistochemistry assays
• Molecular diagnostic systems
• Digital pathology imaging
• Companion diagnostics

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Instruments and Systems: Roche Tissue Diagnostics generates revenue through sale of diagnostic instruments including automated staining systems, PCR platforms, and clinical chemistry analyzers. Instruments are sold to laboratories and healthcare facilities with accompanying consumables, reagents, and software.
2. Diagnostic Reagents and Assays: Recurring revenue from consumable reagents, assay kits, and test cartridges used on Roche diagnostic platforms. Includes IHC assays, molecular diagnostics tests (HIV, HBV, HCV, CT/NG, etc.), and tissue-based companion diagnostics.
3. Companion Diagnostics: Partnering with pharmaceutical companies to develop and commercialize companion diagnostic tests for targeted therapies, particularly in oncology.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Roche Tissue Diagnostics develops, manufactures, and commercializes in vitro diagnostic instruments, consumable reagents, and assays used by pathology, molecular, and clinical laboratories. Core offerings include automated immunohistochemistry and in situ hybridization staining systems (VENTANA BenchMark ULTRA), PCR-based molecular diagnostic platforms (cobas 5800/6800/8800), clinical chemistry analyzers (cobas c 703, cobas ISE neo), digital PCR (Digital LightCycler), next-generation sequencing (AXELIOS 1), and digital pathology whole slide imaging (Digital Pathology Dx), supported by companion diagnostic partnerships with pharmaceutical companies.

Product overview

Roche Tissue Diagnostics operates primarily under the VENTANA brand, offering a comprehensive tissue diagnostics portfolio including automated IHC/ISH staining systems (BenchMark ULTRA), digital pathology solutions (Digital Pathology Dx whole slide imaging), and companion diagnostics. The broader Roche Diagnostics organization encompasses molecular diagnostics (cobas 5800/6800/8800 systems for PCR-based NAT), clinical chemistry (cobas c 703, ISE neo), digital PCR (Digital LightCycler), sequencing (AXELIOS 1), and specialized assays (Elecsys pTau181 for Alzheimer's, cobas BKV for transplant monitoring). LightMix assays extend molecular testing capabilities for research applications.

Differentiator

Problem solved

Functional benefit

Brands

• VENTANA: Brand for automated slide staining systems and tissue-based diagnostics products
• cobas
• navify
• LightCycler
• Elecsys
• BenchMark ULTRA
• Digital Pathology Dx

Products and services

• VENTANA BenchMark ULTRA Automated Staining System Automated immunohistochemistry (IHC) and in situ hybridization (ISH) staining platform for clinical biomarker analysis in cancer diagnostics; processes blood samples and fixed cancer cell lines for immunophenotyping across drug targets. For hospital pathology laboratories and pharmaceutical drug development programs.
• Roche Digital Pathology Dx Whole Slide Imaging System Digital pathology whole slide imaging system that enables primary diagnosis in surgical pathology, validated as comparable to traditional microscopy for diagnostic accuracy. For hospital pathology laboratories and surgical pathologists.
• cobas 5800 System Automated molecular diagnostic system for PCR-based nucleic acid testing (NAT) combining sample processing, amplification, and detection in a compact footprint. For clinical and molecular laboratories performing blood-borne disease, respiratory, sexual health, and transplant testing.
• Digital LightCycler System Digital PCR instrument using microfluidic partitioning for absolute quantification of nucleic acid targets without standard curves, with 6 optical channels, 3 nanowell plate configurations, and 5x concentrated DNA/RNA master mixes. For molecular laboratories performing oncology, transplant, and infectious disease testing.
• cobas c 703 Analytical Unit High-throughput clinical chemistry analyzer designed to double throughput on cobas pro integrated solutions; up to 2,000 tests per hour with 70 reagent positions and automated maintenance. For hospital core laboratories performing high-volume clinical chemistry testing.
• cobas ISE neo Analytical Unit Self-contained ion-selective electrode module for sodium, potassium, and chloride testing; up to 1,800 tests/hour with automated calibration and simplified reagent management. For hospital core laboratories.
• cobas BKV Quantitative Test In vitro nucleic acid amplification test for BK virus DNA quantitation in EDTA plasma and urine, with dual target assay design. Aids in management of BKV in kidney and hematopoietic stem cell transplant patients; runs on the cobas 5800/6800/8800 systems.
• AXELIOS 1 Sequencing Platform Next-generation sequencing platform featuring proprietary SBX technology combining accuracy, speed, flexibility, scalability, and cost efficiency. Research Use Only; not commercially available in the United States. For research and esoteric diagnostic laboratories.
• Elecsys pTau181 Blood Test FDA-cleared blood-based biomarker test for primary care use to rule out Alzheimer's-related amyloid pathology; first FDA-cleared Alzheimer's diagnostic for the primary care setting. For primary care physicians, neurologists, and clinical laboratories.
• LightMix and LightMix Modular Assays Research-use-only molecular assays developed by TIB Molbiol for use on LightCycler systems. Over 200 life science research assays covering genetic, respiratory, pathogen, gastrointestinal, and oncology testing areas. For research laboratories.

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

Partnerships

Two partnerships are on record, tiered minor and core.

• CelLBxHealthminorStrategic or Co-development Partner · 5 November 2025CelLBxHealth presented proof-of-concept demonstrating compatibility of its Parsortix circulating tumor cell (CTC) platform with Roche Tissue Diagnostics' BenchMark ULTRA automated staining system. The study showed successful biomarker analysis across three ADC drug targets (HER2, TROP2, PSMA), processing blood samples and fixed cancer cell lines for immunophenotyping. The partnership explores CTC-based liquid biopsy as an alternative to tissue biopsies for ADC cancer therapy development.
• TIB MolbiolcoreTechnology or IntegrationOver 20-year partnership where TIB Molbiol develops LightMix and LightMix Modular assays exclusively for Roche instruments including LightCycler systems. Over 200 Life Science Research assays available covering genetic, respiratory, pathogen, gastrointestinal, and oncology testing areas. TIB Molbiol assays distributed exclusively through Roche Diagnostics.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bio-Rad Laboratories: Provides clinical diagnostics including digital PCR (QX series), life science research instruments, and clinical chemistry products. The QX digital PCR platform competes directly with Roche's Digital LightCycler System in oncology and infectious disease applications.
• Agilent Technologies (Dako): Through its Dako pathology solutions business, Agilent offers automated IHC/ISH staining systems (Dako Omnis) and a comprehensive antibody and reagent portfolio directly competing with Roche VENTANA in clinical pathology labs.
• Qiagen: Offers molecular diagnostics sample-prep and PCR testing solutions (QIAstat-Dx, QIAsymphony) used in clinical labs alongside companion diagnostic development partnerships with pharma. Directly comparable in molecular testing workflows and CDx development.
• Leica Biosystems (Danaher): Direct competitor in tissue diagnostics, offering the BOND-III automated IHC/ISH staining system and a broad portfolio of primary antibodies and ISH probes. Competes head-to-head with Roche's VENTANA and BenchMark ULTRA platforms in pathology laboratories worldwide.

Regional players

• Hologic: Provides molecular diagnostics (Panther system, Aptima assays) primarily in women's health, infectious disease, and oncology. Overlaps with Roche's cobas molecular testing menu in sexual health, CT/NG, and HPV-related testing.

Emerging players

• PathAI: AI-driven digital pathology company developing machine learning algorithms for biomarker analysis and companion diagnostics. Identified alongside Roche as a key player in the AI-based digital pathology market, representing both an emerging competitor and a potential partner for Roche's digital pathology Dx platform.
• Paige AI: AI-based digital pathology company with FDA-authorized algorithms for cancer detection in tissue samples. Competes with Roche in the AI-pathology segment and is named alongside Roche and PathAI as a key player in the global AI-based digital pathology market.

Broad incumbents

• Danaher Corporation: Parent company of Leica Biosystems and Beckman Coulter Diagnostics, operating in flow cytometry, clinical chemistry, and tissue diagnostics. Provides a broader alternative to Roche's integrated diagnostics portfolio with significant pathology presence.
• BD (Becton, Dickinson and Company): Through BD Biosciences and BD Diagnostics, offers flow cytometry, molecular diagnostics (Max System), and clinical lab solutions with overlapping presence in pathology, infectious disease, and core lab markets relevant to Roche's portfolio.
• Abbott Diagnostics: Operates a broad diagnostics portfolio including clinical chemistry, immunoassay, and molecular diagnostics platforms (Alinity ci, m2000) that overlap with Roche's cobas and ARCHITECT-style core lab and molecular offerings, particularly in core laboratories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/roche

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Tissue Diagnostics